Chemestmed
Private Company
Funding information not available
Overview
Chemestmed is a preclinical-stage biotech pioneering a novel approach to drug discovery by targeting the epitranscriptome, specifically the m⁶A RNA modification pathway. Its core platform focuses on developing small-molecule activators of the METTL3/METTL14 methyltransferase complex to restore healthy RNA methylation levels, with applications in Parkinson's disease, anxiety, type 2 diabetes, and obesity. The company, led by a team with deep scientific and pharmaceutical industry expertise, is also developing inhibitors against other epitranscriptomic targets like METTL16 and FTO for oncology. Operating as a private, pre-revenue entity, Chemestmed aims to address previously undruggable pathways in major disease areas.
Technology Platform
Epitranscriptomics platform for discovering small-molecule drugs that modulate RNA modifications, with a core focus on activators of the METTL3/METTL14 methyltransferase complex to increase m⁶A RNA methylation, and inhibitors of targets like FTO, ALKBH5, and METTL16.
Opportunities
Risk Factors
Competitive Landscape
The epitranscriptomics therapeutics field is growing, with competitors like Storm Therapeutics, Accent Therapeutics, and Gotham Therapeutics (now part of Gilead) developing inhibitors of m⁶A writers (e.g., METTL3) or erasers (e.g., FTO). Chemestmed's focus on *activators* of METTL3 is a key point of differentiation. Large pharma, including Pfizer and AstraZeneca, also have research initiatives in this space.